

DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-249.
2. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: Epidemiology and risk factors. *Int J Womens Health.* 2019;11:287-299.
3. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC. Cell origins of high grade serous ovarian cancer. *Cancers (Basel).* 2018;10(11):1-28.
4. Gaitskell K, Hermon C, Barnes I, Pirie K, Floud S, Green J, et. al. Ovarian cancer survival by stage, histotype, and prediagnostic lifestyle factors, in the prospective UK million women study. *Cancer Epidemiol.* 2022;76:1-8.
5. Fortner RT, Trewin-Nybråten CB, Paulsen AT, Langseth H. Cancer epidemiology : Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway. *Int J Cancer.* 2023;153(5):969-978.
6. Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. First line management of advanced high grade serous ovarian cancer. *Curr Oncol Rep.* 2020;22(6):64-76.
7. Pinto P, Burgetova A, Cibula D, Haldorsen IS, Indrielle-Kelly T, Fischerova D. Prediction of surgical outcome in advanced ovarian cancer by imaging and laparoscopy: A narrative review. *Cancers (Basel).* 2023;15(6):1904-1933.
8. Hoare JI, Hockings H, Saxena J, Silva VL, Maniati E, Mirza HB, et al. Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer. *bioRxiv.*2020:1-20.
9. Elshami M, Tuffaha A, Yaseen A, et al. Awareness of ovarian cancer risk and protective factors: A national cross-sectional study from Palestine. *PLoS One.* 2022;17:1-14.
10. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
11. Toufakis V, Katuwal S, Pukkala E, Tapanainen JS. Impact of parity on the incidence of ovarian cancer subtypes: a population based case control study. *Acta Oncol (Madr).* 2021;60(7):850-855.
12. Ding N, Zhan J, Shi Y, Qiao T, Li P, Zhang T. Obesity in children and adolescents and the risk of ovarian cancer: A systematic review and dose response meta-analysis. *PLoS One.* 2022;17(12):1-14.
13. Colozza D & Padmita AC. Analisis lanskap kelebihan berat badan & obesitas di Indonesia. Jakarta: UNICEF; 2019:26-35.
14. Snell RS. Perineum, organ genitalia feminina, dan persalinan. In: Suwahjo A, Liestuawan YA, eds. *Anatomi klinis berdasarkan sistem.* 9th ed. Sugiharto L, translator. Jakarta: EGC; 2012:809-811.
15. Sherwood L. Prinsip-prinsip endokrinologi. In: Suyono YJ, Iskandar M, Isella V, et al., eds. *Fisiologi manusia dari sel ke sistem.* 9th ed. Mandra LI & Hartanto H, translator. Jakarta: EGC; 2018:766-767.

16. Ellenson LH, Pirog EC. The female genital tract. In: Kumar V, Abbas AK, Aster JC, Turner J, eds. Robbins & cotran pathologic basis of disease. 10th ed. Canada: Elsevier; 2021:1017-1023.
17. Kurman R.J. Carcangiu ML, Herrington CS, Young RH. Tumours of the ovary. In: WHO Classification of tumours of female reproductive organs. 04th ed. France: Lyon: IARC; 2014:1-34.
18. Torre LA, Trabert B, Desantis CE, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(4):284-296.
19. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018;29:1-18.
20. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. *Am J Pathol.* 2016;186(4):733-747.
21. Ravindran F, Choudhary B. Ovarian cancer: molecular classification and targeted therapy. *Ovarian Cancer - Updates in Tumour Biology and Therapeutics.* IntechOpen; 2021:2-3.
22. Yi M, Li T, Niu M, Luo S, Chu Q, Wu K. Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. *Biomark Res.* 2021;9(1):1-12.
23. Mahyenda N, Muhammad S, Asri A. Hubungan skor RMI dengan stadium kanker ovarium tipe epitel di RSUP Dr. M. Djamil Padang. *J Ilmu Kesehatan Indones.* 2023;3(3):210-216.
24. Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. *Gynecol Oncol.* 2018;150(1):85-91.
25. Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, et al. Histological subtypes of ovarian cancer associated with parity and breastfeeding in the prospective million women study. *Int J Cancer.* 2018;142(2):281-289.
26. Husby A, Wohlfahrt J, Melbye M. Pregnancy duration and ovarian cancer risk: A 50-year nationwide cohort study. *Int J cancer.* 2022;151(10):1717-1725.
27. Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. *Br J Cancer.* 2017;116(7):964-971.
28. S. Zayyan M. Risk Factors for Ovarian Cancer. In: *Tumor Progression and Metastasis.* IntechOpen; 2020:1-28.
29. Yang H, Dai H, Li L, Wang X, Wang P, Song F, et al. Age at menarche and epithelial ovarian cancer risk: A meta-analysis and mendelian randomization study. *Cancer Med.* 2019;8(8):4012-4022.
30. Brett M. R, Jennifer B. P, Thomas A. S, Brett M. R, Jennifer B. P, Thomas A. S. Epidemiology of ovarian cancer: a review. *Cancer Biol Med.* 2017;14(1):9-32.
31. Simkova SS, Dvorackova O, Velemínsky M. Assessment of healthy lifestyles in relation to BMI. *Neuro Endocrinol Lett.* 2022;43(7-8):393-399.

32. Anic K, Varchola J, Schmidt MW, Schwab R, Linz VC, Schmidt M, et al. Influence of interdisciplinary frailty screening on perioperative complication rates in elderly ovarian cancer patients: Results of a retrospective observational study. *Arch Gynecol Obstet*. 2022;307:1929-1940.
33. Bandera E, Lee V, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Impact of body mass index on ovarian cancer survival varies by stage. *Br J Cancer*. 2017;117(2):282-289.
34. Chang CYY, Lin KYH, Huang CC, Lin WC. Association of pelvic inflammatory disease (PID) with ovarian cancer: A nationwide population-based retrospective cohort study from Taiwan. *BMC Womens Health*. 2021;21(1):1-7.
35. Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Is pelvic inflammatory disease a risk factor for ovarian cancer?. *Cancer Epidemiol Biomarkers Prev*. 2017;26(1):104-109.
36. Muhammad S, Yasin GMA. Relations between the incidence of endometriosis and type I epithelial ovarian cancer at M Djamil Central Hospital of Padang Indonesia. *Bali Med J*. 2023;12(1):119-122.
37. Brillhante AVM, Augusto KL, Portela MC, Sucupira LCG, Oliveira LAF, Pouchaim AJMV, et al. Endometriosis and ovarian cancer: An integrative review (endometriosis and ovarian cancer). *Asian Pacific J Cancer Prev*. 2017;18(1):11-16.
38. Song K, Dai L, Long X, Wang W, Di W. Follicle stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase. *Sci Rep*. 2020;10(1):1-13.
39. Zhu H, Zhu X, Zheng L, Hu X, Sun LZ, Zhu X. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications. *Oncotarget*. 2017;8(17):29395-29405.
40. Group C, Cancer O. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. *Lancet*. 2015;385(9980):1835-1842.
41. Liu Y, Ma L, Yang X, Bie J, Li D, Sun C, et al. Menopausal hormone replacement therapy and the risk of ovarian cancer: A meta analysis. *Front Endocrinol (Lausanne)*. 2019;10(801):1-19.
42. Hozayen R, Ismael R, Alani W, Fida M, Alkhalifa MA, Rencuzogullari S, et al. The prevalence of positive family history of malignancy among patients with gynecologic cancers in the Kingdom of Bahrain : A retrospective cross sectional study. *Cancer Rep*. 2022;6:1-3.
43. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynecol Obstet*. 2018;143:59-78.
44. Varol U, Kucukzeybek Y, Alacacioglu A, Somali I, Altun Z, Aktas S, et al. BRCA genes: BRCA 1 and BRCA 2. *J BUON*. 2018;23(4):862-866.
45. Budiana ING, Angelina M, Pemayun TGA. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J Turkish-German Gynecol Assoc*. 2019;20(1):47-54.
46. Lisio MA, Fu L, Goyeneche A, Gao Z hua, Telleria C. High grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. *Int J Mol Sci*. 2019;20(4):952.

47. Dilley J, Burnell M, Gentry-Maharaj A, Ryan A, Neophytou C, Apostolidou S, et al. Ovarian cancer symptoms, routes to diagnosis and survival: Population cohort study in the 'no screen' arm of the UK collaborative trial of ovarian cancer screening. *Gynecol Oncol*. 2020;158(2):316-322.
48. Brocklehurst P, Berter S, Brown I, Cruickshank D, Hall M, Hawe J. Ovarian cancer: Recognition and initial management. London: NICE; 2011:1-17.
49. Shetty J, P. P, Pandey D, P. MA. Modified goff symptom index: Simple triage tool for ovarian malignancy. *Sultan Qaboos Univ Med J*. 2015;15(3):370-375.
50. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. *Am Fam Physician*. 2016;93(11):937-944.
51. Committee on the State of the Science in Ovarian Cancer Research. Diagnosis and treatment. In: *Ovarian cancers: Evolving paradigms in research and care*. Washington DC: National Academies Press; 2016:147-188.
52. Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. *Hematol Clin NA*. 2018;32(6):943-964.
53. Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR. Current and emerging methods for ovarian cancer screening and diagnostics: A comprehensive review. *Cancers (Basel)*. 2022;14(12):2885-2931.
54. Sugondo S. Obesitas. In: *Buku Ajar Penyakit Dalam*. 6th ed. Jakarta: Interna Publishing; 2014: 2559-2568.
55. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. *Metabolism*. 2019;92:121-135.
56. Yang J, Zaman MM, Vlasakov I, et al. Adipocytes promote ovarian cancer chemoresistance. *Sci Rep*. 2019;9(1):1-12.
57. Yang J, Stack MS. Lipid regulatory proteins as potential therapeutic targets for ovarian cancer in obese women. *Cancers (Basel)*. 2020;12(11):1-25.
58. Wichmann IA, Cuello MA. Obesity and gynecological cancers: A toxic relationship. *Obstet Gynecol Surv*. 2022;77(11):658-659.
59. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, et al. Preconceptional and prenatal care. In: *Williams obstetrics*. 24th ed. New York: McGraw-Hill Education; 2014:170-171.
60. Sköld C. Impact of pregnancies on ovarian cancer: Risk, prognosis and tumor biology(dissertation). Uppsala: Acta Universitatis Upsaliensis; 2021:1-33.
61. Salehiniya Hamid. Is pregnancy characteristic associated with ovarian cancer? A review of the available evidence. *Eurasian J Med Oncol*. 2022;6(3):198-209.
62. Main C, Chen X, Zhao M, Chamley LW, Chen Q. Understanding how pregnancy protects against ovarian and endometrial cancer development: fetal antigens may be involved. *Endocrinology*. 2022;163(11):1-6.
63. Putri FH. Hubungan kadar CA-125 dengan gambaran histopatologi pasien kanker ovarium epitelial di RSUP Dr. M. Djamil. Universitas Andalas; 2019:1-82.

64. Samuel C, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, et al. Etiology and pathogenesis of epithelial ovarian cancer. *Dis Markers*. 2007;23(5-6):367-376.
65. Rampersad AC, Wang Y, Smith ER, Xu X. Menopause and ovarian cancer risk : mechanisms and experimental support. *Am J Clin Exp Obs Gynecol*. 2015;2(1):14-23.
66. Irsan B, Pradjatmo H, Lutfi M. Hubungan antara modified glasgow prognostic score (mGPS) dengan stadium dan derajat diferensiasi kanker ovarium. *J Kesehat Reproduksi*. 2021;7(3):160.
67. Handoko AL, Jayadi T, Putra ERK, Kusumosih TAR. Hubungan antara obesitas dengan kanker ovarium di Rumah Sakit Bethesda Yogyakarta. *J Kedokt Meditek*. 2023;29(1):27-33.
68. Winarto H, Habiburrahman M, Febriana IS, Kusuma F, Nuryanto KH, Anggraeni TD, et al. Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women. *Oncol Lett*. 2023;25(1):1-18.
69. Mediano MFF, Sichieri R. Insulin resistance influences weight loss in non-obese women who followed a home-based exercise program and slight caloric restriction. *Diabetes Res Clin Pract*. 2011;92(3):361-367.
70. Simamora RPA, Hanriko R, Sari RDP. Hubungan usia , jumlah paritas , dan usia menarche terhadap derajat histopatologi kanker ovarium di RSUD Dr . H . Abdul Moeloek Bandar Lampung tahun 2015-2016. *Majority*. 2018;7(2):7-13.
71. Sköld C, Børge T, Ekblom A, Engeland A, Gissler M, Grotmol T, et al. Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women. *Int J Cancer*. 2018;143(8):1858-1867.
72. Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, et al. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *Br J Cancer*. 2019;121(2):180-192.
73. Fortner RT, Rice MS, Knutsen SF, Orlich MJ, Visvanathan K, Patel AV, et al. Ovarian cancer risk factor associations by primary anatomic site: The ovarian cancer cohort consortium. *Cancer Epidemiol Biomarkers Prev*. 2020;29(10):2010-2018.
74. Nishikawa H, Goto M, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Cancer cachexia: Its mechanism and clinical significance. *Int J Mol Sci*. 2021;22(16):8491.
75. Beehler GP, Sekhon M, Baker JA, Teter B, McCann S, Rodabaugh K, et al. Risk of ovarian cancer associated with BMI varies by menopausal status. *J Nutr*. 2006;136(11):2881-2886.
76. Urbute A, Frederiksen K, Kjaer SK. Early adulthood overweight and obesity and risk of premenopausal ovarian cancer, and premenopausal breast cancer including receptor status: Prospective cohort study of nearly 500,000 Danish women. *Ann Epidemiol*. 2022;70:61-67.
77. Ellwanger B, Schöler-Toprak S, Jochem C, Leitzmann MF, Baurecht H. Anthropometric factors and the risk of ovarian cancer: A systematic review and meta-analysis. *Cancer Rep*. 2022;5(11):1-10.

78. Nababan EHF, Sihotang J, Sasputra IN, Damanik EMB. Faktor risiko kanker ovarium jenis epitelial di RSUD Prof. Dr.W.Z Johannes kota Kupang Nusa Tenggara Timur tahun 2016-2019. *Cendana Med J.* 2021;9(2):198-206.
79. Stewart LM, Spilsbury K, Jordan S, Stewart C, Holman C, Powell A, et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. *Cancer Epidemiol.* 2018;55:110-116.
80. Dakeng S, Porntadavity S, Patmasiriwat P. BRCA1 and TP53 mutations in ovarian cancer: Molecular genetic insights and updated situations in Thailand. *Genomics Genet.* 2018;11:26-34.

